Literature DB >> 2076718

Interference from digoxin-like immunoreactive substance(s) in commercial digoxin kit assay methods.

R G Morris1, D B Frewin, N C Saccoia, W L Goldsworthy, W S Jeffries, A J McPhee.   

Abstract

We have examined the current state of interference by digoxin-like immunoreactive substance(s) (DLIS) in 10 commercially available digoxin assay methods, ie 5 radioimmunoassays (RIA) and 5 non-radioactive immunoassays. Fifty-five specimens of maternal venous blood (30 from third trimester pregnancy and 25 at delivery) and 32 cord samples from their offspring were tested (none of the subjects being medicated with digoxin). The results demonstrated a wide range of DLIS interference with values up to 1.1 micrograms.l-1 being obtained in the cord blood specimens. Of the methods tested the "Coat-a Count" RIA (Diagnostic Products Corporation) and the EMIT column method (Syva) run on the Cobas MIRA (Roche) consistently showed the least interference with respect to all 3 sources of specimens. The Delfia Method (LKB/Wallac) consistently showed the greatest crossreactivity with DLIS. The present study thus demonstrates that DLIS interference persists in several commercial digoxin methods and suggests that the use of data obtained from such methods may compromise patient management.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076718     DOI: 10.1007/BF00315410

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Endogenous digoxin-like immunoreactivity in congestive heart failure.

Authors:  L Shilo; A Adawi; G Solomon; L Shenkman
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-15

2.  Seven different digoxin immunoassay kits compared with respect to interference by a digoxin-like immunoreactive substance in serum from premature and full-term infants.

Authors:  M R Pudek; D W Seccombe; B E Jacobson; M F Whitfield
Journal:  Clin Chem       Date:  1983-11       Impact factor: 8.327

3.  Falsely raised plasma digoxin concentrations in liver disease.

Authors:  A A Nanji; D C Greenway
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-09

4.  Digoxin-like immunoreactive substance in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E F Wijdicks; M Vermeulen; P van Brummelen; N C den Boer; J van Gijn
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

5.  Circulating digitalis-like compounds in essential hypertension.

Authors:  M A Devynck; M G Pernollet; J F Cloix; H de The; L Kamal; J L Elghozi; J Rosenfeld; P Meyer
Journal:  Clin Exp Hypertens A       Date:  1984

6.  Endogenous substance in newborn infants causing false positive digoxin measurements.

Authors:  R Valdes; S W Graves; B A Brown; M Landt
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

7.  Improved interassay correlation of digoxin results in patients with and without renal failure by elimination of digoxin-like immunoreactive factors.

Authors:  W F Skogen; M R Rea; R Valdes
Journal:  Clin Chem       Date:  1987-06       Impact factor: 8.327

8.  Endogenous digoxin-like immunoreactive factors eliminated from serum samples by hydrophobic silica-gel extraction and enzyme immunoassay.

Authors:  W F Skogen; M R Rea; R Valdes
Journal:  Clin Chem       Date:  1987-03       Impact factor: 8.327

9.  Digoxin-like immunoreactivity eliminated from serum by centrifugal ultrafiltration before fluorescence polarization immunoassay of digoxin.

Authors:  R H Christenson; S D Studenberg; S Beck-Davis; F A Sedor
Journal:  Clin Chem       Date:  1987-04       Impact factor: 8.327

10.  Digoxin-like substance in the serum of uremic patients before and after hemodialysis.

Authors:  Z Durakovic; D Ivanovic; A Durakovic
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

View more
  1 in total

1.  Digoxin-like immunoreactive substance levels in cord blood obtained from twins.

Authors:  R G Morris; D B Frewin; N C Saccoia; A J McPhee; W L Goldsworthy
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.